SCHEMBL17217518

SCHEMBL17217518

CCc1ccc(CO/N=[C]\c2cccc(OC)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 8/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ APP P05067 1/20 0.41
▸ FFAR1 O14842 1/20 0.40
▸ IDO1 P14902 2/20 0.39
▸ AGXT P21549 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.38
▸ ABCB1 P08183 1/20 0.38
▸ TUBB4A P04350 1/20 0.37
▸ TUBB P07437 1/20 0.37
▸ TUBA3C P0DPH7 1/20 0.37
▸ TUBA1B P68363 1/20 0.37
▸ TUBA4A P68366 1/20 0.37
▸ TUBB4B P68371 1/20 0.37
▸ TUBB3 Q13509 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217519 1.00 MAOB (0.42) MAOBMEN1KMT2ANPC1RAB9A
SCHEMBL17218035 0.93 MAOB (0.47) MAOBNPC1RAB9AAPPFFAR1
SCHEMBL17218037 0.93 MAOB (0.47) MAOBNPC1RAB9AAPPFFAR1
SCHEMBL17217347 0.90 IDO1 (0.44) MAOBRAB9ASMN1; SMN2FFAR1IDO1
SCHEMBL17217349 0.90 IDO1 (0.44) MAOBRAB9ASMN1; SMN2FFAR1IDO1
SCHEMBL17218010 0.89 MAOB (0.56) MAOBNPC1RAB9AAPPFFAR1
SCHEMBL17218778 0.89 MAOB (0.41) MAOBNPC1RAB9ASMN1; SMN2APP
SCHEMBL17218781 0.89 MAOB (0.41) MAOBNPC1RAB9ASMN1; SMN2APP
SCHEMBL17218009 0.89 MAOB (0.56) MAOBNPC1RAB9AAPPFFAR1
SCHEMBL17217352 0.89 MAOB (0.54) MAOBFFAR1IDO1AGXTABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 MAOB 3611/4885MEN1 1163/4885KMT2A 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback